President & CEO
Intensity Therapeutics Inc.
Lewis H. Bender is the Founder, President and CEO of Intensity Therapeutics, a clinical stage biotechnology company listed on Nasdaq (INTS). The Company is pioneering a novel immune-based drug therapy approach to treat cancer. Lew led the Company from an idea to an on-going, international clinical trial at leading U.S. and Canadian academic hospitals. The Company has collaboration partnerships with the National Cancer Institute, Merck and Bristol Myers Squibb. FDA has designated the Company’s drug for FAST TRACK to treat triple negative breast cancer and orphan drug status for soft tissue sarcoma (STS). Worldwide, patent and trademark Offices including the U.S. have granted the Company patents for protection in 37 countries. Lew was selected by PharmaVOICE as one of the 100 most inspiring people in the life sciences in 2019. The Company has enrolled over 200 subjects in its trials and is initiated a phase 3 global study in STS.
Lew has over 30 years of biotech and pharmaceutical R&D experience. Prior to his founding of Intensity Therapeutics, Lew was the CEO of Interleukin Genetics, a personalized medicine company and held numerous executive positions at the drug delivery company Emisphere Technologies, Inc. including CEO. He is the author of dozens of scientific papers and business publications about of the pharmaceutical industry. Lew has both a Bachelors and Masters of Science degree in Chemical Engineering from MIT, His MBA/MA degrees are from Wharton/Lauder programs. Raised in the United States, Mr. Bender spent several years living in Switzerland and is fluent in French and German along with Swiss-German dialect.
